We are very pleased to announce the rescheduling of our flagship event, the Life Sciences Panorama on November 18th from 12 to 2:30pm EST | 6pm to 8:30pm CET | 9am to 11:30am PST. This event is free and open to all!

Since its inception eight years ago, the Life Sciences Panorama has grown strong and is now recognized by the life science community as an annual catalyst for knowledge exchange. This must-attend event will focus this year on:

Deconstructing the Cost of Healthcare in Uncertain Times: the evolving US roadmap to pricing, market access and reimbursement for drugs, medical devices, apps and other healthcare innovations.

You will hear from highly regarded experts on the challenges in reimbursement and market access strategy, how to value the therapeutic benefits of your product even at early stage and what value really means to an investor or to a payer.

Topics:

• Whether you are developing a new medical device, an app or a new therapy, when do you need a reimbursement and market access strategy? 
• What is the general commonality, the “formula”, that has to be proven to payers?
• What does value mean to payers?
• What type of data and studies are actually needed to prove that a drug, app or device need to be reimbursed?

New! Dedicated Breakout Sessions

Since this event is now fully virtual, each participant will have the opportunity to participate in dedicated breakout sessions, moderated by our panelists. These breakout sessions will allow for an interactive 30 minute Q&A discussion where meeting participants can exchange with speakers in a session of their choice. Experts will share their knowledge on the following topics:

• Breakout Session 1: Value to payers and evidence needs for the US market.
• Breakout Session 2: Value of advancing market access and health economic efforts when considering investors, partners and corporate strategy.

Connect with participants!

At the end of the event, feel free to take advantage of our networking sessions moderated by the French American Biotechnology Springboard (FABS).

Get to know our sponsors and partners!

After the panel discussion and the breakout sessions, you will be able to visit the exhibitor hall of digital sponsors booths and connect one-on-one with a representative, access to video links and presentations.

We will be using the event platform, Hopin. To get started have a look at this short demo video to get familiar with Hopin.

Master of Ceremony

Jim Shanahan, Co-founder and Chief Business Officer @ SynDevRx, Inc and FABS Co-Founder

Jim is a serial entrepreneur with expertise in establishing and managing start-ups, including obtaining financing, developing core messaging and establishing key clients. Ability to seize on great ideas and develop business strategies to turn them into products, to attract and retain top industry talent, to understand and to effectively communicate complex technical ideas, to create and execute business plans, and to effectively execute on sales and marketing plans. Experience in multiple industries, including biotech drug development, consumer electronics, and audio electronics.  Jim is currently Chief Business Officer at SynDevRx, Inc., a Cambridge company focusing on the link between cancer and metabolic hormone dysfunction.

Opening remarks

Subject: How the current pandemic has changed the landscape on value proposition and the importance of pricing

Dr Susan Garfield, US Advisory Principal and Life Sciences Sector Commercial Lead at EY

An accomplished strategist, consultant, and thought leader, Susan leads the commercial team within EY Life Sciences Advisory and strategy teams. Her career in life sciences spans 20 years. Prior to joining EY in 2015, she held various executive positions at consulting firms and life sciences and healthcare companies. Currently, she works with EY life sciences clients on pioneering strategies and commercial transformation programs. She received a DrPH in Health Policy and Management from Boston University’s School of Public Health and an SM in Health Policy and Management from Harvard TH Chan School of Public Health. She also has an MSc in Population and Development from The London School of Economics and Political Science and a BA in English and Women’s Studies from the University of Pennsylvania.

Panel Moderator

Roman Casciano, General Manager and SVP in Analytica Laser, Certara’s Evidence and Access Group

Roman Casciano is the General Manager and SVP with Certara where he leads the Evidence and Access division focused on market access and value demonstration for Certara’s life sciences customers. Based in New York City, Roman’s role is to provide leadership of strategic and scientific teams across the division’s eight offices and three service lines.

As an applied health economist and market access strategist, Roman has personally led hundreds of engagements in the international market access and health economics context related to product value demonstration and has deep experience in the management of multidisciplinary teams of scientific and strategic consultants across continents in support of drug development and access strategy. Roman’s experience ranges from analytical activities such as economic modelling and database studies, to strategic activities such as developing product pricing and market access plans and communicating evidence internally and externally for our customers. Roman has experience across the product lifecycle, including assessment of early phase assets, licensing due diligence, and development strategy, as well as later in the life cycle including launch planning and commercialization activities.

Roman was a founding member of the Analytica Group in 1997 and has been with the company since, including roles as General Manager of the company’s German subsidiary, and a lead role in the drug development team at Analytica’s previous parent company, Accentia Biopharmaceuticals.  Roman received both a Bachelor of Science degree in Mechanical and Aerospace Engineering and a Master of Engineering Degree in Mechanical Engineering and Engineering Decision Making from Cornell University.

Panelists

Michael Epstein, Head of Commercial Strategy at Ascenian Consulting

Michael Epstein is Head of Commercial Strategy at Ascenian Consulting, which specializes in evidence generation, positioning, pricing and value demonstration for health technologies. Mr Epstein helps Ascenian’s clients develop commercialization strategies that optimize access and uptake in the US, EU5 and Canada. Prior to Ascenian, Mr. Epstein was Principal in Global Market Access Consulting at Evidera, Director of Commercial Strategy and Reimbursement at United BioSource Corporation, and held specialized health technology commercialization consulting roles at Harris Interactive (now Nielsen), Roger Green and Associates, MedSpan and TVG. His research has been published in peer-reviewed journals such as J Ambulatory Paediatrics and has been presented at international conferences such as ECTRIMS. He has spoken at industry meetings such as CBI Forecasting for Personalized Medicines, and he has moderated payer panels at conferences such as ISPOR Europe. Mr Epstein holds an MS in public policy analysis, MA in political science, and BA magna cum laude in political science from the University of Rochester.

Erin Mistry, Senior Vice President, Head of Payer Strategy, Gov’t Affairs & Trade Relations, CorMedix Inc

Erin Mistry has more than 15 years experience working in the rapidly evolving pharmaceutical and biotech industry with a focus on commercial strategy, portfolio prioritization, government affairs and policy considerations as well as deep expertise in pricing, access and reimbursement strategies. Currently Senior Vice President of Payer Strategy, Government Affairs and Trade Relations at CorMedix, Erin is responsible for all aspects of pricing, policy and contracting for a product launching in end-stage renal disease.

On the service side of the business, Erin was responsible for leading a team of 55 pricing, access, and HEOR consultants across global markets launching 10 assets across 8 therapeutic categories including oncology, rare/orphan diseases, diabetes, infectious disease, metabolic disorders, ophthalmology, CNS, microbiome, cardiovascular, and opioid addiction.

Erin has worked directly with VC firms and PE to help identify strategic assets in clinical trial development for commercial viability, indication prioritization, in close cooperation with their biotech leadership. Erin received her M.S. in Biomechanical Engineering and B.S. in Industrial Engineering Healthcare track from North Carolina State University.

Peter J. Neumann, Sc.D., Director, Center for the Evaluation of Value and Risk in Health at Institute for Clinical Research and Health Policy Studies at Tufts Medical Center. Professor of Medicine, Tufts University School of Medicine

Peter J. Neumann, Sc.D., is Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. He is the founder and director of the Cost-Effectiveness Registry, a comprehensive database of cost-effectiveness analyses in health care. Dr. Neumann has written widely on the role of clinical and economic evidence in pharmaceutical decision making and on regulatory and reimbursement issues in health care. He served as co-chair of the 2^nd Panel on Cost-Effectiveness in Health and Medicine. He is the author or co-author of over 300 papers in the medical literature, the author of Using Cost-Effectiveness Analysis to Improve Health Care (Oxford University Press, 2005) and co-editor of Cost-Effectiveness in Health and Medicine, 2^nd Edition (Oxford University Press, 2016). Dr. Neumann has served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He is a member of the editorial advisory board of Health Affairs and the health policy advisory board for the Congressional Budget Office.  He has also held several policy positions in Washington, including Special Assistant to the Administrator at the Health Care Financing Administration. He received his doctorate in health policy and management from Harvard University.

John Tagliamonte, Entrepreneur-in-residence at MassBio

John Tagliamonte has more than 20 years of experience in executive leadership with responsibility for corporate development, finance, commercial and business operations, strategic planning, finance and legal functions with established and emerging public and private life sciences companies.  As the first Entrepreneur-in-Residence with the MassBio, he was responsible for forward-looking program content across the organization, while helping to develop the next generation of biotech entrepreneurs.

He also serves on the business advisory boards of oncology drug startups WntRx and PercpTx.  Previously he was Chief Business Officer of rare disease company Oxyrane and held various executive business leadership roles at Anchor Therapeutics, ImmunoGen and Johnson & Johnson, as well as venture investing with Safeguard Scientifics. He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad.  John received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.

12 pm: Introduction and presentations by Jim Shanahan

12:10pm: Opening Remarks by Dr Susan Garfield

12:30pm: Panel discussion:

Deconstructing the Cost of Healthcare in Uncertain Times: the evolving US roadmap to pricing, market access and reimbursement for drugs, medical devices, apps and other healthcare innovations.

1:10pm: Breakout Discussion Sessions

• Breakout Session 1: Value to payers and evidence needs for the US market.
  Moderated by Roman Casciano, Erin Mistry and Peter Neumann
• Breakout Session 2: Value of advancing market access and health economic efforts when considering investors, partners and corporate strategy
  Moderated by Jim Shanahan, Mike Epstein and John Tagliamonte

1:45pm: Closing Remarks by Jim Shanahan and Roman Casciano

2pm: Networking session in Breakout rooms moderated by the French American Biotech Springboard (FABS)

2:30pm: End of the event

This event is made possible thanks to the support of our sponsors:

Our partners:

About Life Sciences Panorama:

Life Science Panorama is an annual event organized by the French American Biotechnology Springboard and powered by FACCNE (the French American Chamber of Commerce of New England), a leading Chamber of Commerce in the US. Since starting the first edition of the Life Science Panorama eight years ago, this event has grown strong and is now recognized by the life science community as an annual catalyst for knowledge exchange. This must-attend event addresses core topics of interest for companies at different stages of growth and offers fantastic networking opportunities for biopharma professionals.

Learn about 2019 edition of LSP 

About the French American Biotechnology Springboard (FABS):

The French-American Biotechnology Springboard (FABS) is a forum comprised of experienced French and American experts and leaders coming from Massachusetts-based biotechnology and pharmaceutical companies. The aim of the French-American Biotechnology Springboard (FABS) is to guide French Bio-Entrepreneurs in the highly-specific scientific, business, and cultural environment of New England.

REGISTER NOW